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In the past several years many laboratories have studied the signif-
icance of α and β tubulin proteins in antimicrotubule drug resis-
tance. These studies have extended to several antimicrotubule
agents in various carcinoma cell lines. Early studies showed muta-
tions and alterations in the steady state soluble and polymerized α
and β tubulin fractions in drug resistant cell lines (Schibler and
Cabral, 1986; Cabral et al, 1986; Minotti et al, 1991). Although the
existence of different α and β tubulin isotypes and their tissue
specific expression was reported in the past, only recently demon-
strated were the effects of individual β tubulin isotypes on overall
microtubule functions including assembly, dynamics, drug sensi-
tivity and drug binding. Banerjee et al (1990) have shown that β III
isotype depleted tubulin assembles into microtubules at a faster
rate than unfractioned tubulin. These microtubules are also more
sensitive to paclitaxel-induced assembly compared to unfractioned
tubulin (Lu and Luduena, 1993). Subsequent studies revealed
alterations in the expression of specific β tubulin isotypes as result
of antimicrotubule drug resistance (Haber et al, 1995; Ranganathan
et al, 1996; 1998a; 1998b; Kavallaris et al, 1997; Kavallaris et al,
1999). In addition, combination studies have shown that cyclosporin
A enhances paclitaxel efficacy in lung carcinoma cell lines by
modulating β tubulin isotype composition (Ross and Antoniono,
1999). Recently, Kavallaris et al, (1999) have shown that antisense
oligonucleotides to β III isotype sensitized the drug resistant cells
to paclitaxel. In addition, mutations in β I isotype were reported in
paclitaxel resistant human ovarian carcinoma cells (Giannakakou
et al, 1997), breast carcinoma cells (Wiesen and Horwitz, 2000)
and non-small-cell lung cancer patients (Monzo et al, 1999) with
tumours that were unresponsive to paclitaxel therapy. 
Antimicrotubule drug resistance associated changes in tubulin
isotypes prompted several investigators to determine the contribu-
tion of individual isotypes by transfecting cells and examining
their antimicrotubule drug response. Wu et al (1998) have shown
that transfection of β IVa isotype into human leukemic cell line
failed to confer resistance to paclitaxel. Blade et al (1999) have
over-expressed rodent β I, β II or β IVb isotypes in CHO cells and
shown that these isotypes do not confer resistance to paclitaxel.
Our previous work demonstrated increases in β III and β IVa isotypes
in human prostate carcinoma cells that were made resistant to
estramustine or paclitaxel (Ranganathan et al, 1996, 1998a). In
addition, acute exposures to these agents resulted in elevations of
β III levels. To further understand the function of β III isotype in
antimicrotubule drug response, parental DU145 human carcinoma
cells were transfected with the human β III cDNA. The results
presented herein indicate that regulation of tubulin in cells is
complex and that attempts to increase levels of a single isotype
may lead to compensatory changes in the expression of other
isotypes. 
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Summary Increases of individual β tubulin isotypes in antimicrotubule drug resistant cell lines have been reported by several laboratories. We
have previously described elevations in β III and β IVa isotypes in estramustine and paclitaxel resistant human prostate carcinoma cells. To
investigate further the function of β tubulin isotypes in antimicrotubule drug response, human prostate carcinoma cells that normally have very
low to undetectable levels of β III were stably transfected with β III cDNA in pZeoSV system. An 18 bp haemagglutinin (HA) epitope tag was
added at the 3′ end prior to cloning into the vector. Cells were transfected with pZeoSV or pZeoSV-β III plasmids and selected in the presence
of Zeocin. Immunofluorescent staining of the transfectant cells have shown significant expression and incorporation of HA-tagged β III tubulin
into cellular microtubules. Quantitation of Western blots revealed the HA-tagged β III levels to be approximately 7-fold higher than the vector
control cells. RT-PCR analysis confirmed the increase at the transcript level and also revealed a collateral increase of β II and β IVb transcripts.
Cell viability assays indicated that sensitivity of β III transfected cells to various antimicrotubule agents was similar to vector transfected cells:
IC50 values for estramustine, paclitaxel, colchicine and vinblastine were 4 µ M, 4 nM, 22 nM and 2 nM, respectively for both cell lines. Thus,
overexpression of β III isotype in human prostate carcinoma cells by stable transfection failed to confer antimicrotubule drug resistance to these
cells. Counterregulatory increases of endogenous β II and  β IVb tubulin isotypes in these β III transfected cells may be a compensatory
mechanism used by the cells to overcome the effects of elevated β III levels on the cellular microtubules. These results highlight the difficulty in
isolating the contribution of single tubulin isotypes in drug response studies. © 2001 Cancer Research Campaign http://www.bjcancer.com 
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Construction of expression vectors and selection of
transfectants 
Human β III cDNA that was previously cloned in our laboratory
(Ranganathan et al, 1998b) was inserted into the HindIII and XhoI
sites of pZeoSV vector (Invitrogen, Carlsbad, CA). An 18 bp
haemagglutinin tag (HA) was added at the C-terminus to distin-
guish the vector driven β III protein from the endogenous protein.
Human prostate carcinoma (DU145) cells were transfected with
pZeoSV or pZeoβ III DNA by using superfect (Qiagen, Santa
Clarita, CA) according to manufacturer’s protocol. Cells were
placed in drug selection medium containing 100 µ g/mL Zeocin
and clones were selected. 
Immunofluorescent staining of human β III-transfectant
cells 
β III-transfectant and vector-transfectant cells were plated onto
glass coverslips and allowed to attach. Cells were fixed in 4%
paraformaldehyde and stained in the following manner. Cells were
treated with 3% BSA in phosphate buffered saline (PBS) for 30
min to block for non-specific binding of the antibodies. Cells were
then stained with the following antibodies diluted in 1% BSA/PBS
for 90 min at 37˚C: pan α tubulin antibodies, pan β tubulin anti-
bodies (1:200, Sigma Chemical Co., St. Louis, MO), β II, β III and
β IV isotype-specific antibodies (1:100, Biogenex, San Ramon, CA)
and haemagglutinin antibodies (1:500, BabCo, Richmond, CA).
Cells were stained with rhodamine-red-x conjugated antimouse
secondary antibodies (1:800, Jacksonville Immunoresearch,) for
45 min at 37˚C, mounted onto slides, and examined. Images were
captured with 12 bit cooled CCD (Quantix, Photometrics, Tuscon,
AZ) and average pixel intensity values were quantitated and
analysed by using Isee software (Inovision Corp., Raleigh/Durham,
NC). At least 200 cells were quantited per each antibody stain and
the average pixel intensities were calculated. 
Western blot analysis of proteins from β III-transfectant
and vector-transfectant cells 
Cytosolic fractions were prepared from the cells and Western blots
were analysed as described previously (Ranganathan et al, 1996).
Briefly, cells were lysed for 10 min at 4˚C in PBS containing 1%
Triton X100, 0.1% SDS, 0.5% Sodium deoxycholate and protease
inhibitors, followed by centrifugation at 10 000 × g for 10 min.
Protein concentrations of the supernatants were estimated by the
Biorad method (Hercules, CA). Proteins were fractionated by 8%
polyacrylamide gel electrophoresis and transferred onto PVDF
membranes (Millipore, Bedford, MA). Western blots were probed
with antibodies against HA epitope (1:500) and β III tubulin isotype
(1:200) and developed using ECL plus chemiluminiscence detec-
tion system (Amersham Pharmacia Biotech, Piscataway, NJ).
Results were quantitated by densitometric scanning of the films. 
RT-PCR analysis of β tubulin isotype transcripts from
pZeoSV and pZeoβ III-transfectant cells 
RNA was isolated from both cell lines using RNAeasy kit from
Qiagen Inc (Chadsworth, CA). β tubulin isotype-specific primers
for the β I, β II, β III, β IVa and β IVb isotypes and the PCR conditions
were described in detail previously (Ranganathan et al, 1996). In
addition, vector-specific and HA epitope specific primers were
chosen using the primer detective program (Clontech, Palo Alto,
CA) and synthesized by the DNA core facility at Fox Chase
Cancer Center. PCR products were analysed by agarose gel
electrophoresis and quantitated by densitometric scanning. 
Cytotoxicity assays 
ZeoSV and Zeoβ III transfectant cell lines were plated onto 96-well
cell culture plates and allowed to attach. Estramustine was a 
gift from Kabi Pharmacia, Lund, Sweden (now Pharmacia,
Bridgewater, NJ). Paclitaxel, vinblastine and colchicine were
purchased from Sigma Chemical Co. Cells were exposed to
various concentrations of the drugs for 48 h, fixed and stained with
sulforhodamine B, as previously described (Ranganathan et al,
1996). Absorbance was measured at 560 nm and cell survivals in
both cell lines were determined. 
RESULTS 
Expression of β III tubulin isotype by transfection 
When the cells were stained with antibodies against HA epitope,
β III transfected cells showed significant staining for the HA epitope
in the microtubules, indicating β III protein was derived from the
pZeoβ III DNA and was incorporated into cellular microtubules
(Figure 1D). By contrast, staining for the vector-transfected cells
was similar to background level of staining (Figure 1C). When the
cells were stained with the antibodies against β III isotype, a 2.4-fold
increase in staining was seen in the β III transfectant cells (Figure
1B) compared to the vector transfected cells (Figure 1A). Cells
were also stained with antibodies against pan α and pan β tubulin
proteins to determine if the over-expression of β III isotype had any
affect on the overall β and α tubulin levels (Figure 1 E–H). As
shown in the figure, levels of β tubulin levels did not change signif-
icantly from vector-transfected cells (Figure 1E) to β III transfected
cells (Figure 1F). There was a 1.8-fold increase of overall α tubulin
levels in β III transfected cells (Figure 1H) compared to vector trans-
fectant cells (Figure 1G). Quantiation of immunofluorescent
staining was done as described in the Methods section and the
results are shown in Table 1. 
Western blot analysis of the proteins from the transfectant cell
lines by use of HA antibodies has confirmed the increase seen by
immunofluorescence (Figure 2). Quantitation of the Western blot
by NIH image analysis software revealed a 7-fold increase in the
HA signal. There were no differences in the overall β tubulin and β
tubulin levels between the vector transfected and β III transfected
cell lines. 
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Table 1 Quantitation of immunofluorescent images of β III transfected and
vector transfected cells stained with antibodies. Cells were stained, images
were captured and average pixel intensities were quantitated as described in
the Methods section 
Antibody used Vector-transfectants β III transfectants 
β III tubulin 339 ± 24 828 ± 33 
HA-tag 89 ± 17 407 ± 55 
Pan β -tubulin 637 ± 67 866 ± 33 
Pan α -tubulin 610 ± 42 1120 ± 27 
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Figure 1 Immunofluorescent staining of pZeoSV (A, C, E, G) and pZeoβ III (B, D, F, H) transfectants. Cells were plated onto coverslips, fixed and stained with
the indicated antibodies as described in the Methods section. (A, B) β III tubulin isotype, (C, D) HA-epitope tag, (E, F) pan β tubulin, and (G, H) pan α tubulin
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Figure 3 (A) RT-PCR analysis of β tubulin transcripts from vector transfected and β III transfected cells. RNA was isolated from both cell lines, RT-PCR was performed
with primers for individual β tubulin isotypes and analysed by agarose gel electrophoresis as described in the Methods. (B) Immunofluorescent staining of pZeoSV and
pZeoβ III transfectant cells. Cells were plated onto coverslips, fixed and stained with antibodies against β II (A, B) and β IV (C, D) isotypes as described in Methods
Figure 2 Western blot analysis of pZeoSV and pZeoβ III transfectants. Cell lysates were prepared, run on 8% polyacrylamide gels, transferred onto membranes
and probed with the appropriate antibodies as described in the Methods section
pZeoSV pZeoβ III pZeoSV pZeoβ III
β II
β IVb β IVa
β III
β I
HA tagged β III
A
A B
C D
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β III transfectant cells 
RT-PCR analysis of RNA from the transfectant cells has shown
that there was a significant increase of β III isotype mRNA, as seen
by the elevation of overall β III levels and HA tagged β III levels.
(Figure 3A). Quantitation of the image revealed a 3-fold increase
of β III transcript levels compared to vector transfectants. There was
a significant level of HA tagged β III transcript compared to no
signal in the vector transfectants. β I and β IVa levels were similar in
both cell lines. Interestingly, a collateral increase in the levels of β II
and  β IVb transcripts was seen in the β III transfected cells. The
increases were quantified to be 7-fold and 2-fold for β II and β IVb
transcripts, respectively. Immunofluorescent staining of the cells
with corresponding antibodies has confirmed the increase at the
protein level (Figure 3B). 
Antimicrotubule drug response of transfectant cells 
β III transfectant and vector control cell lines were treated with
estramustine, paclitaxel, colchicine and vinblastine for 48 h, and
dose response curves were determined (Figure 4). Cytotoxicity
profiles of both cell lines were similar for each of the antimicro-
tubule agents tested, with IC50 values of 4 µ M, 4nM and 2nM
for estramustine, paclitaxel and vinblastine, respectively. For
colchicine, the IC50 values were 15 and 17nM for β III transfected
and vector transfected cells. Cell doubling times for β III transfec-
tant and vector control cell lines were found to be very similar, ~22 h
indicating that transfection of β III into cells did not alter cell cycle
times. 
DISCUSSION 
Several in vitro studies have demonstrated that the β tubulin
isotype composition of microtubules determines the differences in
their functions including dynamics, assembly properties and sensi-
tivity to antimicrotubule agents (Banerjee et al, 1990, 1992;
Benerjee and Luduena, 1992; Lu and Luduena, 1993, 1994; Panda
et al, 1994, 1997; Derry et al, 1997). Because antimicrotubule
agents are widely used in cancer therapy, tubulin isotype composi-
tion of tumour cells may be an important factor in the success of
therapy. Estramustine, vinblastine and paclitaxel have been shown
to suppress microtubule dynamics at very low drug concentrations
(Jordan et al, 1993, 1996; Dhamodharan et al, 1995; Panda et al,
1997). Work by Lu and Luduena (1993) demonstrated that micro-
tubules lacking the β III isotype polymerized at a faster rate in the
presence of paclitaxel than the microtubules from unfractioned
tubulin. Derry et al (1997) have shown that suppression of micro-
tubule dynamics by paclitaxel varies according to β tubulin isotype
content, with αβ III microtubules and αβ IV microtubules being
approximately 7-fold less sensitive to the drug than the micro-
tubules from unfractionated tubulin. 
Work from many laboratories including our own has shown that
cancer cell lines made resistant to antimicrotubule agents have
altered tubulin isotype composition. In addition, Kavallaris et al
(1999) have shown that antisense oligonucleotides to β III isotype
sensitized paclitaxel resistant lung cancer cells to the drug.
However, the data presented in this paper demonstrate that trans-
fection and 3-fold over-expression of β III isotype in cells does not
confer resistance to estramustine or paclitaxel. Increases of β
tubulin isotypes seen in drug resistant cell lines might be due to the
β III tubulin transfectant prostate carcinoma cells 739
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Figure 4 Dose response curves of pZeoSV and pZeoβ III cell lines. Cells were plated onto 96-well plates, allowed to attach and treated with indicated doses
of antimicrotubule agents for 48 h. Cells were then fixed and stained with sulforhodamine B and cell survivals were determined as described in the methods. 
(A) estramustine, (B) paclitaxel, (C) colchicine, (D) vinblastine
BJOC 01-1956 735-740  20/8/01  3:20 pm  Page 739selection with antimicrotubule agents. Another reason for the lack
of antimicrotubule drug resistance of β III transfectant cells might
be the collateral increases of β II and β IVb levels. Cellular β tubulin
levels are under autoregulation through cotranslational degrada-
tion of mRNAs (Theodorakis and Cleveland, 1992; Bachurski 
et al, 1994). In addition, Gonzalez-Garay and Cabral (1995) have
shown that over-expression of β I tubulin in Chinese hamster ovary
cells resulted in coordinate increase of α tubulin levels. Based on
the collateral increases of β II and β IVb levels in our β III transfectant
cells, it is possible to conceive that cells compensate for over-
expression of β III by autoregulation of these isotypes. 
Tubulin isotypes differ significantly from each other in their
assembly properties (Lu and Luduena, 1994). Microtubules from
αβ II and αβ IV assembled much faster than unfractionated tubulin.
αβ III dimers assembled at a very slow rate and had the highest
critical concentration. However, in vitro analysis by Panda et al
(1994) has shown that microtubules assembled from αβ III dimers
were more dynamic than the microtubules from αβ II and  αβ IV
isotypes. They further demonstrated that addition of αβ II dimers 
to  αβ III dimers suppressed microtubule dynamics. In addition,
colchicine binding characteristics of αβ III dimers were signifi-
cantly different from αβ II and αβ IV dimers, with apparant on-rate
constants of 132 ± 5, 30 ± 2 and 236 ± 7 M–1s–1 for αβ II, αβ III and
αβ IV dimers, respectively (Banerjee and Luduena, 1992). The data
presented in this paper together with existing in vitro data support
the hypothesis that cells might modulate their microtubule func-
tions by altering tubulin isotype composition. The lack of antimi-
crotubule resistance seen in our β III transfectants, β IVa transfectants
(Wu et al, 1999) and the rodent β I, β II or β IVb transfectants (Blade 
et al, 1999) altogether point to the conclusion that the β tubulin
regulation is highly complex. When cells are transfected with an
individual β tubulin isotype, cellular compensatory mechanisms
come into play, including altered expression of endogenous β
tubulin isotypes, which may alter the effects of the transfected
isotype. 
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